CN1957971A - Health products for decreasing blood fat - Google Patents
Health products for decreasing blood fat Download PDFInfo
- Publication number
- CN1957971A CN1957971A CN 200610131614 CN200610131614A CN1957971A CN 1957971 A CN1957971 A CN 1957971A CN 200610131614 CN200610131614 CN 200610131614 CN 200610131614 A CN200610131614 A CN 200610131614A CN 1957971 A CN1957971 A CN 1957971A
- Authority
- CN
- China
- Prior art keywords
- natto
- fat reducing
- group
- health product
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036541 health Effects 0.000 title claims description 14
- 210000004369 blood Anatomy 0.000 title abstract description 27
- 239000008280 blood Substances 0.000 title abstract description 27
- 230000003247 decreasing effect Effects 0.000 title abstract 2
- 235000013557 nattō Nutrition 0.000 claims abstract description 25
- 229920001491 Lentinan Polymers 0.000 claims abstract description 14
- 229940115286 lentinan Drugs 0.000 claims abstract description 14
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 9
- 230000001603 reducing effect Effects 0.000 claims description 23
- 239000002775 capsule Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 240000000599 Lentinula edodes Species 0.000 claims description 9
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- 235000013824 polyphenols Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000003518 caustics Substances 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 238000012869 ethanol precipitation Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002333 glycines Chemical class 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 13
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940086319 nattokinase Drugs 0.000 description 3
- 108010073682 nattokinase Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010058646 Arcus lipoides Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- -1 flavanol compound Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A hypolipemic health-care food for decreasing blood fat, blood sugar, and blood pressure, improving immunity, dissolving thrombus and resisting against virus and tumor is proportionally prepared from natto powder, lentinan, kakonein, and theapolyphenol through mixing.
Description
Technical field:
The present invention relates to a kind of health food of blood fat reducing.
Background technology:
Hyperlipemia be meant cholesterol in serum (TC), triglyceride (TG) and (or) low density lipoprotein, LDL (LDL) too high and (or) a kind of whole body lipid metabolism that serum high-density LP (HDL) is low excessively is unusual.Every serum cholesterol＞5.72 mMs/liter (220 milligrams/deciliter) or (with) triglyceride＞1.70 mMs/liter (150 milligrams/deciliter) or (with) high density lipoprotein 64 mMs/liter (140 milligrams/deciliter) person, diagnosable is hyperlipemia.Hyperlipemia initial stage majority does not have clinical symptoms, but does not in time correct, to the infringement of health be concealment, gradually, carrying out property and general.Its direct infringement is to quicken systemic atherosclerosis, because the vitals of whole body all will rely on tremulous pulse blood supply, oxygen supply, in case tremulous pulse is stopped up by atheromatous plaque, will cause serious consequence.The renal failure that arteriosclerosis causes etc., all closely related with hyperlipemia.A large amount of research datas show that hyperlipemia is apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death is independent and important risk.In addition, hyperlipemia also is an important risk factor that promotes hypertension, impaired glucose tolerance, diabetes.Hyperlipemia also can cause fatty liver, liver cirrhosis, cholelithiasis, pancreatitis, retinal hemorrhage, blind, peripheral vascular disease, limping, hyperuricemia.Xanthoma around tendon shape, nodositas, palm plane and the eye socket, arcus juvenilis etc. also can appear in some constitutional and familial hyperlipidemia patient.
The medicine majority of treatment hyperlipemia is the chemical drugs of chemosynthesis or the Chinese medicine compound of being made up of several Chinese medicines at present, the former toxicity occurs by life-time service, and effect is undesirable, and latter's mechanism of action is indeterminate, is difficult to grasp the standardization and the quantification of effective ingredient.Therefore screening the blood fat reducing effective ingredient at present from food, health product and natural goods commonly used, make up these blood lipid-lowering medicine or health product that effective ingredient exploitation toxicity is low, effect is strong then, is very promising development approach.But the health product that lack highly effective blood fat reducing on the market.
Summary of the invention
The objective of the invention is to have effect for reducing blood fat and blood fat reducing effective ingredient nontoxic, that have no side effect by screening in food commonly used, the natural goods, these effective ingredient science processing, rational proportion prepares blood fat reducing healthcare food again.
Common food natto, Lentinus Edodes, green tea and medicinal and edible Chinese medicine Radix Puerariae have effect for reducing blood fat, simultaneously by having studies have shown that its blood fat reducing effective ingredient.The said proportioning of the present invention is such, is made up of the tea polyphenols that extracts in puerarin that extracts in the lentinan that extracts in the Lentinus Edodes, natto refined powder, the medicinal and edible Chinese medicine Radix Puerariae and the green tea.These compositions cooperatively interact, synergism, the toxicity that emulsifying fat, anti-oxidation, acceleration lipid metabolism, final eliminating fat are packed up.Thereby the generation of blood fat reducing, prevention of arterial sclerosis and coronary heart disease, human body immunity improving power, constitutional effect.
Technical scheme of the present invention by following component by weight percentage composition mix and to form:
Natto powder 65-84% lentinan 1.0-2.5%
Puerarin 2.8-7.8% tea polyphenols 8-25%.
Be the conclusive evidence product quality, all working all should carry out in clean and dry environment.
1) extraction of lentinan, the extraction of lentinan should be avoided carrying out in strong acid, aqueous slkali, otherwise very easily cause glycosidic bond fracture and conformation change in the lentinan.Earlier mushroom fruiting body is pulverized, with 90-100 ℃ of water stirring and leaching 3-5h, 2-3 time, the extracting of reuse 5moI/L caustic lye of soda tentatively is divided into polysaccharide water-soluble and molten 2 parts of alkali.Remove the Lentinus Edodes slag then, the supernatant resin method is removed small molecular weight impurity, can get crude product behind ethanol precipitation.
2) preparation of natto powder, the Semen Glycines of getting after selected was soaked in water 10-24 hour, make it fully steep out the back under the temperature that (contains 100 ℃) more than 100 ℃ steaming and decocting 20-60 minute, when the ripe bean after the steaming and decocting is cooled to 20-40 ℃, evenly spray into Bacillus natto liquid, cultivated 18-30 hour at temperature 35-45 ℃, relative humidity 50-90% condition bottom fermentation.The natto that will ferment (producing more transparent haircuts) places the interior cold preservation of 0-10 ℃ of cold room more than 24 hours, takes out, and carries out lyophilization, pulverizes, and crosses the 40-80 mesh sieve, promptly.
3) tea polyphenols is bought by market.
4) puerarin is bought by market.
These health product No. 0 capsule of can packing into after by the above-mentioned raw materials mix homogeneously is packed.
Natto is that Semen sojae atricolor passes through a kind of folk food that Bacillus natto forms by fermentation.Natto not only contains rich in protein, also contains lecithin, saponin, oligosaccharide, isoflavone, nattokinase, superoxide dismutase, albumen inhibitory enzyme, multivitamin, 19 seed amino acids, 22 kinds of multiple compositions that human body is highly profitable such as trace element.To eat natto a lot of to the benefit of health more, can prevent and treat heart disease, apoplexy, cancer, osteoporosis.The microbial digestive tract disease of obesity and cause of disease.And, do not find also that to order edible natto has any toxic and side effects to human body.Because the medical care effect of natto obtains more and more and admitting more and more widely, at present, natto has become a kind of health food that prevails in Japan, Canada, some countries of US and European, popularizes as a kind of bread and cheese and health product at China's natto.Natto has become universally acknowledged medical-care health food, be because not only its raw soybeans is a kind of health-care nutritive food, and, Bacillus subtilis natto (Bacillus natto) is secreted again in the process of fermented soybean and has been synthesized a variety of enzymes, vitamin, aminoacid and other have only distinctive nutrient of natto and biological active substances, as nattokinase (Nattokinase, NK), Pylazine, antibacterial peptide, VK2.Wherein, NK and Pylazine are two kinds and directly connect thrombolytic active substance with asking in human bodies, not only can stop thrombosis formation but also can thrombus, they can effectively prevent and treat myocardial infarction, cerebral infarction, mortality rate diseases such as apoplexy to net this.Contain nourishing healthy materials such as essential fatty acid, vitamin E, oligosaccharide, dietary fiber, flavonoid, Saponin in addition in the natto, these nutrient substance have blood fat reducing, blood pressure lowering, prevent that health care such as arteriosclerosis can be used for crowds' such as hyperlipidemia, hypertension, bran urine disease, heart disease food and health food.Natto is except being easier to than Semen sojae atricolor to absorb, and linoleic acid that it contains and lecithin help cleaning sedimentary cholesterol in the blood vessel, purifies the blood and impels cell metabolism.Natto protein helps improving blood vessel elasticity, prevents hypertensive effect.
Lentinus Edodes (Lentinula edodes (Berk.) Pegler) has another name called fragrant bacterium, Lentinus Edodes, is a kind of important edible medicinal cultivation fungus.Lentinan is the p-1 of a kind of molecular weight between 40-80 ten thousand that is separated to from mushroom fruiting body, the 3-glucosan, have antiviral, antitumor, adjusting immunologic function, the clinical treatment that is mainly used in malignant tumor such as gastric cancer, pulmonary carcinoma, intestinal cancer and cancerous ascites pleural fluid all has better action to the immunologic function that improves hepatitis and aids patient etc. in addition.By studies have shown that in recent years, Lentinus Edodes has blood fat reducing and vessel softening effect, and wherein main effective ingredient is a lentinan, and it is the most obvious to reduce the cholesterolemia effect in the lentinan effect for reducing blood fat.
Tea polyphenols is a kind of natural antioxidant that extracts from Folium Camelliae sinensis, contains 6 kinds of compositions such as catechin, anthocyanidin, flavanol compound, pattern Citrus chachiensis Hort., flavonols and phenolic acid, has antibiotic, anticancer, defying age, uvioresistant and the effect of elimination free radical.Recent pharmacological research shows that tea polyphenols has, pharmacological functions such as fat-reducing slimming, blood sugar lowering and cholesterol, angiocardiopathy preventing, inhibition tumor cell.
Puerarin is the isoflavonoid that extracts and separate in the dry root of leguminous plant Pueraria lobota, and chemistry respectively is 4,7-dihydroxy-8-β-D glucose isoflavone.Be usually used in treating hypertension, coronary heart disease, high blood viscosity, angina pectoris, cerebral ischemia.Puerarin reaches protection heart and brain and the pure natural plant extract that prevents the arteriosclerosis effect by to nitric oxide production balance adjustment in vascular smooth muscle Endothelin and the blood, is one of main medicine of whole world clinical treatment cardiovascular and cerebrovascular disease at present.Recent study shows that puerarin has blood fat reducing, blood pressure lowering dual regulation effect and being gazed at.The cholesterol reducing effect is obvious especially in the effect for reducing blood fat of puerarin.
The positive effect of component of the present invention is as follows: blood fat reducing, blood glucose, blood pressure, fat-reducing slimming, enhance immunity, thrombus, antiviral, antitumor.
It is as follows to utilize the present invention to carry out blood fat reducing pharmacology result of experiment:
1 materials and methods
1.1 experimental drug is already provided by Yanbian University's grass elixir
1.2 laboratory animal and grouping
Laboratory animal adopts SD rat 140-160g male and female half and half, is provided by animal housing of Medical College.Test divides normal control group (the I group is fed normal diet), high fat matched group (the II group is fed high lipid food), large, medium and small three the dosage groups of test component (III, IV, V group are fed high lipid food, and irritate the capsule of the present invention of 3 various dose of stomach every day).Every group of 12 rats.
1.3 high lipid food is got 91.5% common normal feedstuff powder, 1.3% net cholesterol, 7% lard stearin and natrii tauroglycocholas 0.2% mix homogeneously, makes granule and will do high lipid food.
1.4 after the blood fat reducing test test rat random packet, weigh, get serum lipid concentrations in the tail hematometry serum respectively.The different feedstuff of freely ingesting routinely.Freely drink water, weighed 1 time in per 10 days.After one month, hepatic portal vein hematometry blood fat and hemorheology index are got in anesthesia.
1.5 lipid determination serum total cholesterol (TC) is with high ferro-acetic acid-sulphuric acid development process; Serum triglycerides (TG) is used the isopropyl alcohol extracting, the acetylacetone,2,4-pentanedione development process; Serum high-density LP cholesterol (HDL-C) with behind Sodium phosphotungstate-magnesium precipitate, is measured by literature method; Low-density lipoprotein cholesterol (LDL-C) is calculated according to formula, i.e. LDL-C=TC-(HDL-D+1/5TG).
2 results
2.1 capsule of the present invention is to the influence of rat blood serum T-CHOL.See Table 1.Feed the normal control group (I group) of normal diet, serum cholesterol content does not have significant difference before and after the test; Serum cholesterol content has significant difference before and after hypercholesterolemia group (II group) test, and administration group (III, IV, V group) has been compared significant difference with the hypercholesterolemia group, and along with the increase content of cholesterol of dosage descends.As seen capsule of the present invention has the effect that stops the rat blood serum cholesterol to raise.
Table 1 capsule of the present invention is to the influence of rat blood serum cholesterol
| Group | Dosage g/kg/d | Before the test (mmol.L-1) | Test back (mmol.L-1) |
| I II III IV V | 0 0 0.33 0.66 1.32 | 1.98±0.29 2.03±0.47 1.99±0.36 2.06±0.54 1.98±0.42 | 2.29±0.11 4.28±0.20 3.17±0.19* 2.83±0.25* 2.57±0.15** |
Annotate: compare with the II group, * shows p＜0.05, and * * shows p＜0.01, and following table together.
2.2 capsule of the present invention is to the influence of rat blood serum triglyceride.See Table 2.Feed the normal control group (I group) of normal diet, serum triglycerides content does not have significant difference before and after the test; Serum triglycerides content has significant difference before and after high fat group (II group) test, and administration group (III, IV, V group) has been compared significant difference with high fat group (II group), and descends with the increase triglyceride content of dosage.As seen capsule of the present invention has the effect that stops the rat blood serum triglyceride to raise.
Table 2 capsule of the present invention is to the influence of rat blood serum triglyceride
| Group | Dosage g/kg/d | Before the test (mmol.L-1) | Test back (mmol.L-1) |
| I II III IV V | 0 0 0.33 0.66 1.32 | 1.08±0.19 1.03±0.07 1.15±0.16 1.06±0.11 1.18±0.12 | 1.06±0.07 1.9±0.09 1.30±0.14* 1.20±0.08* 0.95±0.06** |
2.3 capsule of the present invention influences the rat blood serum HDL-C.It the results are shown in Table 3.Feed the normal control group (I group) of normal diet, the serum high-density LP cholesterol does not have significant difference before and after the test;
Table 3 capsule of the present invention is to the influence of rat blood serum HDL-C
| Group | Dosage g/kg/d | Before the test (mmol.L-1) | Test back (mmol.L-1) |
| I II III IV V | 0 0 0.33 0.66 1.32 | 0.68±0.29 0.89±0.47 0.98±0.36 1.01±0.54 0.99±0.42 | 0.62±0.02 1.54±0.08 0.93±0.10 1.62±0.21* 2.38±0.12** |
The serum high-density LP cholesterol has significant difference before and after high fat group (II group) test, heavy dose of administration group (V) and middle dosed administration group (III) relatively have significant difference with high fat group (II), but low dosage administration group (IV) is compared there was no significant difference with high fat group (II).As seen capsule of the present invention has the effect of increasing the rat blood serum HDL-C in heavy dose.
2.4 capsule of the present invention influences the rat blood serum low-density lipoprotein cholesterol.See Table 4.The result is with 2.3.
Table 4 capsule of the present invention is to the influence of rat blood serum low-density lipoprotein cholesterol
| Group | Dosage g/kg/d | Before the test (mmol.L-1) | Test back (mmol.L-1) |
| I II III IV V | 0 0 0.33 0.66 1.32 | - - - - - | 1.46±0.13 2.44±0.24 1.95±0.19 0.96±0.30* 0.21±0.08** |
4 conclusions: the hyperlipidemia model group is compared TC, TG with the normal control group, HDL-C has significant difference.Illustrate that this capsule hinders the rising of the rat fat that is caused by high lipid food.
The specific embodiment:
Mushroom fruiting body is pulverized in the extraction of lentinan, and with 90-100 ℃ of water stirring and leaching 3-5h, 2-3 time, the extracting of reuse .5moI/L caustic lye of soda tentatively is divided into polysaccharide water-soluble and molten 2 parts of alkali.Remove the Lentinus Edodes slag then, the supernatant resin method is removed small molecular weight impurity, can get crude product behind ethanol precipitation.
The preparation of natto powder, the Semen Glycines of getting after selected was soaked in water 10-24 hour, make it fully steep out the back under the temperature that (contains 100 ℃) more than 100 ℃ steaming and decocting 20-60 minute, when the ripe bean after the steaming and decocting is cooled to 20-40 ℃, evenly spray into Bacillus natto liquid, cultivated 18-30 hour at temperature 35-45 ℃, relative humidity 50-90% condition bottom fermentation.The natto that will ferment (producing more transparent haircuts) places the interior cold preservation of 0-10 ℃ of cold room more than 24 hours, takes out, and carries out lyophilization, pulverizes, and crosses the 40-80 mesh sieve, promptly.
Tea polyphenols and puerarin are bought by market.
By the natto powder 327.6g of last method preparation, thick lentinan (lentinan content 20%) 31.37g, puerarin extract (puerarin content 40%) 50.43g, tea polyphenols 40.6g, the capsule of packing into behind the mix homogeneously No. 0 prepares 1000, every heavy 0.45g.
Claims (4)
1, a kind of fat reducing health product, by following component by weight percentage composition mix and to form:
Natto powder 65-84% lentinan 1.0-2.5%
Puerarin 2.8-7.8% tea polyphenols 8-25%.
2, a kind of fat reducing health product according to claim 1, it is characterized in that described natto powder is to make by following method: the Semen Glycines of getting after selected was soaked in water 10-24 hour, make it fully steep out the back under the temperature that (contains 100 ℃) more than 100 ℃ steaming and decocting 20-60 minute, when the ripe bean after the steaming and decocting is cooled to 20-40 ℃, evenly spray into Bacillus natto liquid, at temperature 35-45 ℃, relative humidity 50-90% condition bottom fermentation was cultivated 18-30 hour, the natto that will ferment (producing more transparent haircuts) places the interior cold preservation of 0-10 ℃ of cold room more than 24 hours, take out, carry out lyophilization, pulverize, cross the 40-80 mesh sieve, promptly.
3, a kind of fat reducing health product according to claim 1, it is characterized in that described lentinan is to make by following method: earlier mushroom fruiting body is pulverized, with 90-100 ℃ of water stirring and leaching 3-5h, 2-3 time, the extracting of reuse 5moI/L caustic lye of soda tentatively is divided into polysaccharide water-soluble and the molten two parts of alkali, removes the Lentinus Edodes slag then, the supernatant resin method is removed small molecular weight impurity, gets crude product behind ethanol precipitation.
4, a kind of fat reducing health product according to claim 1 is characterized in that filling composition with No. 0 capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101316149A CN100556418C (en) | 2006-11-02 | 2006-11-02 | A kind of fat reducing health product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101316149A CN100556418C (en) | 2006-11-02 | 2006-11-02 | A kind of fat reducing health product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1957971A true CN1957971A (en) | 2007-05-09 |
| CN100556418C CN100556418C (en) | 2009-11-04 |
Family
ID=38069923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101316149A Expired - Fee Related CN100556418C (en) | 2006-11-02 | 2006-11-02 | A kind of fat reducing health product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100556418C (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874629A (en) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | Total-nutrient multifunctional compound hippophae rhamnoides and natto health-care product |
| CN101874628A (en) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | Total-nutrient multifunctional compound natto and pine pollen health-care product |
| CN102342496A (en) * | 2010-07-27 | 2012-02-08 | 李光敏 | Preparation method of cordyceps militaris natto product |
| CN103330036A (en) * | 2013-07-22 | 2013-10-02 | 北京绿源求证科技发展有限责任公司 | Hypertension prevention food health tea dissolved medicine |
| CN103719864A (en) * | 2014-01-10 | 2014-04-16 | 东北师范大学 | Blood glucose-reducing natto combined capsule and preparation method thereof |
| CN104397701A (en) * | 2014-12-10 | 2015-03-11 | 韦星平 | Hypolipidemic natural food additive |
| CN104585766A (en) * | 2015-02-05 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | Composition as well as preparation method and application thereof |
| CN104814429A (en) * | 2015-04-10 | 2015-08-05 | 山东安然纳米实业发展有限公司 | Healthcare food with functions of liver protection and care and lipid regulation |
| CN107412753A (en) * | 2017-08-08 | 2017-12-01 | 江苏天美健大自然生物工程有限公司 | A kind of controlled release tablet health product containing Nattokinase and preparation method thereof |
| CN110089759A (en) * | 2019-05-07 | 2019-08-06 | 朱国强 | A kind of Combizym food eaten suitable for Patients with Cardiovascular/Cerebrovascular Diseases |
| CN110089758A (en) * | 2019-05-07 | 2019-08-06 | 朱国强 | One kind Combizym food of Nattokinase containing active earthworm protein and preparation method thereof |
| CN110089760A (en) * | 2019-05-07 | 2019-08-06 | 朱国强 | A kind of processing technology of the Combizym of Nattokinase containing active earthworm protein food |
| CN111480758A (en) * | 2019-01-29 | 2020-08-04 | 金振库 | Natto and pollen typhae solid beverage and preparation method thereof |
-
2006
- 2006-11-02 CN CNB2006101316149A patent/CN100556418C/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874629A (en) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | Total-nutrient multifunctional compound hippophae rhamnoides and natto health-care product |
| CN101874628A (en) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | Total-nutrient multifunctional compound natto and pine pollen health-care product |
| CN102342496A (en) * | 2010-07-27 | 2012-02-08 | 李光敏 | Preparation method of cordyceps militaris natto product |
| CN103330036A (en) * | 2013-07-22 | 2013-10-02 | 北京绿源求证科技发展有限责任公司 | Hypertension prevention food health tea dissolved medicine |
| CN103719864A (en) * | 2014-01-10 | 2014-04-16 | 东北师范大学 | Blood glucose-reducing natto combined capsule and preparation method thereof |
| CN104397701A (en) * | 2014-12-10 | 2015-03-11 | 韦星平 | Hypolipidemic natural food additive |
| CN104585766A (en) * | 2015-02-05 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | Composition as well as preparation method and application thereof |
| CN104814429A (en) * | 2015-04-10 | 2015-08-05 | 山东安然纳米实业发展有限公司 | Healthcare food with functions of liver protection and care and lipid regulation |
| CN107412753A (en) * | 2017-08-08 | 2017-12-01 | 江苏天美健大自然生物工程有限公司 | A kind of controlled release tablet health product containing Nattokinase and preparation method thereof |
| CN111480758A (en) * | 2019-01-29 | 2020-08-04 | 金振库 | Natto and pollen typhae solid beverage and preparation method thereof |
| CN110089759A (en) * | 2019-05-07 | 2019-08-06 | 朱国强 | A kind of Combizym food eaten suitable for Patients with Cardiovascular/Cerebrovascular Diseases |
| CN110089758A (en) * | 2019-05-07 | 2019-08-06 | 朱国强 | One kind Combizym food of Nattokinase containing active earthworm protein and preparation method thereof |
| CN110089760A (en) * | 2019-05-07 | 2019-08-06 | 朱国强 | A kind of processing technology of the Combizym of Nattokinase containing active earthworm protein food |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100556418C (en) | 2009-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100556418C (en) | A kind of fat reducing health product | |
| CN101347241B (en) | Nano functional health food and method of processing the same | |
| EP2226071B1 (en) | Composition for oral administration | |
| CN102423375A (en) | Blood lipid-reducing health-care product | |
| CN102406860A (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN101664184A (en) | Healthcare product for reducing blood fat and preparation method thereof | |
| CN1911102B (en) | Compounding agent for sobering and health-care, and its production method | |
| CN102960520B (en) | L-arabinose health-care press candy added with cyclocarya paliurus | |
| US20080124416A1 (en) | Therapeutic composition from goji (lycium barbarum l.), methods of making and using | |
| Basharat et al. | Nutritional and functional profile of carob bean (Ceratonia siliqua): A comprehensive review | |
| CN106901118A (en) | Solid beverage with auxiliary hyperglycemic effect and preparation method thereof | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| CN105533446A (en) | Nutritious oatmeal with health-care effect and preparation method thereof | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| KR20160140417A (en) | Composition for Liver Function Improvement Comprising Natural Extracts | |
| KR102137136B1 (en) | Composition comprising pumpkin hydrolysis extract, amorphophallus paeoniifolius hydrolysis extract, curcuma extract and cacao nibs extract | |
| KR101784093B1 (en) | Manufacturing method of composition having anti-diabetic effect containing the extracts of fermented germinated brown rice and orstachys japonia | |
| CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
| KR101534142B1 (en) | A composition comprising an extract of combined crude drugs for treating and preventing abnormal metabolic diseases | |
| CN101690533B (en) | Manufacturing method of red data tea beverage | |
| CN108450941A (en) | A kind of dietary composition adjusting lipid metaboli | |
| KR100973087B1 (en) | Method method for manufacturing and composition for the treatment of diabetes by-products cultivation | |
| KR101819920B1 (en) | Manufacturing method of composition having anti-diabetic and anti-inflammatory effect containing the extracts of fermented germinated brown rice and cudrania tricuspidata | |
| KR20090092905A (en) | A pharmaceutical composition comprising extract of medicine plants for the treatment and prevention of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091104 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |